June 3, 2015
Nicholas C. Turner of The Royal Marsden and Institute of Cancer Research An add-on of Pfizer Inc.’s anticancer agent Ibrance (palbociclib) to standard hormone therapy significantly extended progression-free survival (PFS) versus hormone therapy alone in women with hormone receptor-positive and...read more